Clinical trial · Interventional
MR-simulation in Radiotherapy for Prostate Cancer
An Exploratory Study to Assess the Feasibility of Incorporating MR in the Radiotherapy Pathway of Patients With Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the feasibility of acquiring an MR scan in the radiotherapy treatment position as part of the patient's radiotherapy pathway and incorporating the data into our radiotherapy planning systems, so that it can be potentially used to reduce healthy tissue exposure to radiation. Subsequently, the protocols and procedures established can be used to put the technique into routine clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the PROSTATE | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI scan | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MR-Simulation
- description
- Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
- interventionNames
- Device: MRI scan
Primary outcomes (1)
- measure
- Standard Operating Procedure (SOP) for MRI-simulation for prostate patients
- timeFrame
- 6 months
- description
- Write a Standard Operating Procedure (SOP) for MRI-scanning of prostate patients in the radiotherapy treatment position so that their data can be used in the treatment planning for either in-direct or MRI-only planning
Secondary outcomes (2)
- measure
- Clinical Protocol for in-direct MRI planning for prostate
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written, voluntary, informed consent * Age ≥ 18 * ECOG Performance Status ≤ 2 * Life expectancy \> 12 months * Histologically proven carcinoma of the prostate * Radical radiotherapy +/- hormones indicated as the primary treatment modality * Staging diagnostic MRI of the prostate need to be available for comparison. * Adequate organ function and absence of other major concurrent illness, allowing Exclusion Criteria: * Inability to provide informed consent * Impaired renal function (serum creatinine of \> 200) * Severely impaired liver function * Patients with allergies or contra-indications to the gadolinium contrast agent that may be used in the study * Severe claustrophobia or inability to tolerate MRI scans * General contra-indications to MRI including cardiac pacemakers and defibrillators, metallic prosthetic devices, aneurysm clips and metal fragments in the eyes, as defined in MRI safety departmental protocols * Serious inter-current conditions or other non-malignant illnesses that are uncontrolled or whose control may be affected by participation in this study * Any patient who has urinary or faecal incontinence * Status greater than or equal to 3
References
Publications (1)
- DERIVEDThomas C, Dregely I, Oksuz I, Guerrero Urbano T, Greener T, King AP, Barrington SF. Effect of synthetic CT on dose-derived toxicity predictors for MR-only prostate radiotherapy. BJR Open. 2024 Jun 3;6(1):tzae014. doi: 10.1093/bjro/tzae014. eCollection 2024 Jan. PMID 38948455